Effects of an acute enteric disease challenge on IGF-1 and IGFBP-3 gene expression in porcine skeletal muscle by Johnson, B.J. et al.
 48
Swine Day 2002 
 
 
EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND 
IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE 
 
B. J. Johnson, J. P. Kayser, J. D. Dunn, A. T. Waylan, 
S. S. Dritz1, J. C. Nietfeld2, and J. E. Minton 
 
 
Summary 
 
Eighteen pigs (initial weight 25 lb and ap-
proximately 5 wk of age) were used in a 14-d 
trial to determine the effects of an acute Sal-
monella enterica serotype typhimurium (ST) 
disease challenge on both circulating insulin-
like growth factor-1 (IGF-1) and insulin-like 
growth factor binding protein-3 (IGFBP-3) 
and steady-state IGF-1 and IGFBP-3 mRNA 
levels in skeletal muscle.  Muscle biopsies and 
blood samples were obtained from all pigs on 
d 0, 3, 7, and 14 relative to ST-challenge.  Re-
sults suggest that an acute ST-challenge de-
creased circulating IGF-1 levels on d 3 and 7 
but did not affect circulating IGFBP-3 concen-
trations.  Additionally, ST-challenge had no 
effect on steady-state IGF-1 and IGFBP-3 
mRNA levels in skeletal muscle following the 
onset of disease.  These data suggest that an 
acute enteric disease insult can lower circulat-
ing IGF-1 but more chronic conditions may be 
necessary to affect local IGF-1 levels in skele-
tal muscle. Additionally, the increased muscle 
IGF-1 mRNA without increased IGFBP-3 lev-
els on d 14 most likely results in increased 
IGF-1 synthesis that contributes to circulating 
IGF-1 concentrations.  
 
(Key Words:  Pigs, Salmonella, Muscle, IGF-
1, IGFBP-3.) 
 
Introduction 
 
Our previous data with an acute enteric 
disease (Salmonella enterica serotype typhi-
murium, ST) challenge showed a precipitous 
decrease in circulating IGF-1 and IGFBP-3 
concentrations 48 h after challenge.  These 
data suggest that alterations in IGF/IGFBP 
levels during a diseased-state may contribute 
to the reduced skeletal muscle protein accre-
tion.  To our knowledge no one has ascer-
tained the effect of an acute enteric disease 
challenge on local IGF-1 and IGFBP-3 syn-
thesis in skeletal muscle tissue.  A more thor-
ough understanding of alterations in local 
IGF-1 and IGFBP-3 mRNA levels in skeletal 
muscles of pigs during an acute disease chal-
lenge will increase our understanding of the 
effect of disease on these important growth 
mediators and, ultimately, protein synthesis 
and degradation in skeletal muscle. The objec-
tive of the current study was to determine the 
effect of an infectious dose of ST on changes 
in steady-state IGF-1 and IGFBP-3 mRNA of 
porcine skeletal muscle. 
 
Procedures 
 
The experimental protocol used in this 
study was approved by the KSU Institutional 
Animal Care and Use Committee.  A total of 
18 pigs (initial weight 25 lb and approxi-
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mately 5 wk of age) were randomly allotted to 
one of two treatments (n=9 pigs per treatment) 
with weight balanced across the treatments in 
a 14-d experiment.  The two treatments were 
control or Salmonella-challenged (ST).  Pre-
ceding the study fecal samples were obtained 
and cultured using standard microbiological 
direct plating and enrichment techniques at the 
Kansas State University Veterinary Diagnostic 
Laboratory to ensure that pigs were not shed-
ding ST prior to challenge. 
 
On d 0, nine pigs were challenged with ST 
using a challenge model described previously.  
Pigs were challenged orally with 11 × 109 cfu 
of ST.  The control pigs received sterile me-
dium orally. 
 
Pigs were weighed and feed disappearance 
was measured on d 0, 7, and 14.  On d 7 after 
challenge, fecal samples were obtained from 
all pigs and cultured for ST at the Kansas 
State University Veterinary Diagnostic Labo-
ratory.  Rectal temperature was measured on 
pigs daily from d 0 to 7.  Blood samples were 
obtained via venipuncture on d 0 (prior to 
challenge), 3, 7, and 14. 
 
Muscle samples (0.5 g) were obtained 
from the gluteus medius of pigs on d 0, 3, 7, 
and 14, relative to disease challenge using a 
biopsy technique.  Briefly, pigs were adminis-
tered general anesthesia.  Once pigs reached a 
surgical plane of anesthesia (approximately 10 
min.) the biopsy site was scrubbed thoroughly 
and a 1-cm incision was performed.  A 
Bergstrom biopsy needle was inserted to ob-
tain approximately 0.5 g of muscle tissue.  
The incision site was closed with tissue adhe-
sive.  Pigs fully recovered within 1.5 hr of the 
procedure.  Muscle samples were immediately 
homogenized in 10 mL of a preservative solu-
tion, followed by rapid freezing in liquid ni-
trogen and stored at -80°C for subsequent 
analysis.  
 
Total RNA was isolated according to es-
tablished procedures.  RNA integrity was de-
termined by electrophoresis of total RNA 
through a 1% agarose formaldehyde gel fol-
lowed by ethidium bromide staining to visual-
ize 28 and 18S ribosomal RNA (rRNA).  Once 
RNA integrity was assessed, any contaminat-
ing DNA was removed.  The RNA (1 ug) was 
reverse transcribed to synthesize the first-
strand of cDNA. 
 
All real-time quantitative (RTQ-PCR) re-
actions were performed on a ABI Prism 7000 
sequence detection system, (Applied Biosys-
tems, Foster City, CA).  Specific cDNA se-
quence, forward and reverse primer se-
quences, and Taq Man detection probe se-
quences were: 
 
IGF-1:  Genbank Accession # M31175, for-
ward primer (38) 
TCTTCTACTTGGCCCTGTGCTT, reverse 
primer (110) GCCCCACAGAGGGTCTCA, 
and TaqMan probe (65) CCTTCAC-
CAGCTCTGCCACGGC 
 
IGFBP-3:  Genbank Accession #AF085482, 
forward primer (692) AGCACG-
GACACCCAGAACTT, reverse primer (753) 
CGGCAAGGCCCGTATTC, and TaqMan 
probe (713) 
TCCTCTGAGTCCAAGCGCGAGA 
 
Relative expression of IGF-1 and IGFBP-3 
were normalized to 18S rRNA with the eu-
karyotic 18S rRNA endogenous control (ABI 
Cat. # 4319413E; Genbank Accession # 
X03205) and were reported as arbitrary units. 
 
Blood collected on d 0, 3, 7, and 14 was 
allowed to clot at 4°C for 48 h and serum har-
vested by centrifugation.  Serum IGF-1 was 
determined via immunoradiometric assay as 
described previously for use in pigs.  Circulat-
ing concentrations of IGFBP-3 were also de-
termined with a commercially available im-
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munoradiometric assay (Diagnostic Systems 
Laboratories, Inc., Webster, TX, Cat. # DSL 
6600).   
 
All data were analyzed with the PROC 
MIXED procedure of SAS as a completely 
randomized design with repeated measures 
over time.  The model included terms for the 
fixed effects of treatment, day, and treatment 
× day interaction.  Unless noted on figures, 
comparisons of treatment or time were con-
ducted only when a significant main effect or 
interaction was found. 
 
Results and Discussion 
 
None of the pigs were shedding ST prior 
to challenge.  On d 7 following challenge, 
77.8 % (7/9) of pigs orally-challenged with ST 
were shedding ST in their feces as compared 
to 0 % (0/9) in the control group.  Rectal tem-
perature in ST-challenged pigs did not differ 
from control pigs during the 14-d trial (data 
not shown).  However, daily feed intake was 
dramatically reduced in pigs challenged with 
ST the first week following challenge as com-
pared to control pigs (0.84 lb/d ± .15 vs. 1.61 
lb/d ± .11). 
 
Circulating IGF-1 levels did not differ 
(P>0.10) between control and ST-challenged 
pigs prior to challenge (Figure 1).  Following 
the oral ST-challenge, infected pigs exhibited 
a precipitous drop in circulating IGF-1 levels 
on d 3 as compared to the d 0 value (33 vs. 97 
ng/mL).  Sera from pigs challenged with ST 
had reduced (P<0.05) IGF-1 on d 3 and 7 as 
compared to sera from control pigs (Figure 1).  
However, by d 14 following challenge, sera 
from ST-infected pigs had similar circulating 
IGF-1 as compared to sera from control pigs, 
suggesting the pigs were recovering from the 
acute disease challenge (Figure 1).  The circu-
lating IGF-1 results need to be viewed with 
some caution.  While the treatment × day in-
teraction tended to be significant (P=0.09) in 
this study, we believe the treatment compari-
sons within day are representative.  First, the 
changes reported here mirror results published 
previously which were obtained from the 
same ST- disease challenge model.  Further-
more, due to the precipitous drop in feed in-
take the first week following ST-challenge, we 
would fully expect circulating IGF-1 concen-
trations to be reduced during this period. 
 
Serum concentrations of IGFBP-3 are il-
lustrated in Figure 2.  No significant (P>0.10) 
treatment × day interaction was observed for 
circulating IGFBP-3.  We did observe a sig-
nificant day effect (P<0.001).  Circulating 
IGFBP-3 in sera from pigs on d 7 and 14 were 
elevated (P<0.01) as compared to samples ob-
tained on d 0 and 3. 
 
The effects of ST-challenge on steady-
state IGF-1 mRNA levels in muscle are illus-
trated in Figure 3a.  No significant treatment × 
day interaction was observed for steady-state 
IGF-1 mRNA levels in muscle of pigs.  How-
ever, we did detect a significant day effect.  
Steady-state IGF-1 mRNA in muscle samples 
obtained on d 14 were significantly greater 
(P<0.001) than d 0, 3, and 7.  In this study, 
skeletal muscle IGF-1 mRNA levels were un-
affected by ST-challenge even though circu-
lating IGF-1 levels were reduced following 
the acute ST-challenge.  These data suggest 
that an acute disease challenge may not be 
sufficient to alter local IGF-1 levels in skeletal 
muscle. However, a more chronic disease 
challenge could lower IGF-1 levels in skeletal 
muscle which would affect protein synthesis 
and degradation rates. 
 
No treatment effect was observed for 
steady-state IGFBP-3 mRNA levels in muscle 
samples obtained by biopsy (Figure 3b).  It is 
noteworthy that during the period of increas-
ing muscle IGF-1 mRNA concentrations (d 
14) local muscle IGFBP-3 mRNA levels were 
unaffected. This difference between responses 
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between muscle IGF-1 and IGFBP-3 gene ex-
pression on d 14 may contribute to increased 
skeletal muscle protein synthesis during peri-
ods of rapid muscle accretion in the growing 
pig.  The increased muscle IGF-1 mRNA 
without increased IGFBP-3 levels on d 14 
most likely results in increased IGF-1 synthe-
sis.  It is likely that this IFG-1 production exits 
the muscle and contributes to the increased 
circulating IGF-1 levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Serum Insulin-Like Growth Factor 1 (IGF-1) Concentrations in ST-Challenged 
and Control Pigs (n=9).  Sera were obtained on d 0, 3, 7, and 14 following chal-
lenge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Serum Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Concentrations 
in ST-Challenged and Control Pigs (n=9).  Sera were obtained on d 0, 3, 7, and 
14 following challenge.  Average (day) values with different superscripts differ 
P<0.05. 
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Figure 3. A) Steady-State Muscle IGF-1 mRNA Levels in Muscle Biopsy Samples Obtained 
from ST-Challenged and Control Pigs on D 0, 3, 7, and 14 Relative to Disease 
Challenge.  IGF-1 mRNA levels were normalized to 18S rRNA and expressed as 
arbitrary units. B) Steady-state muscle IGFBP-3 mRNA levels in muscle biopsy 
samples obtained from ST-challenged and control pigs.  IGFBP-3 mRNA levels 
were normalized to 18S rRNA and expressed as arbitrary units similar to IGF-1. 
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